2026-04-17T18:53:14Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/120142025-10-24T10:36:32Zcom_2072_378070com_2072_378040col_2072_378092

Clinical and economic burden of acute exacerbations of idiopathic pulmonary fibrosis: a prospective observational study in Spain (OASIS study) Romero Ortiz, Ana MORROS, MARTA Ramon, A. MARIA JESUS, RODRIGUEZ NIETO Cano-Jiménez, Esteban Villar, Ana Institut Català de la Salut [Villar Gómez A] Servei de Pneumologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Rodríguez-Nieto MJ] Servicio de Neumología, IIS-Hospital Universitario Fundación Jiménez Díaz, CIBERES, Madrid, Spain. [Cano-Jiménez E] Servicio de Neumología, Hospital Universitario Lucus Augusti, Lugo, Spain. [Romero Ortiz A] Servicio de Neumología, Hospital Universitario Virgen de Las Nieves, Granada, Spain. [Morros M] Adelphi Targis SL, Barcelona, Spain. [Ramon A] Boehringer Ingelheim España, Barcelona, Spain Vall d'Hebron Barcelona Hospital Campus Qüestionaris Assistència sanitària - Cost Fibrosi pulmonar Qualitat de vida - Avaluació ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Epidemiologic Methods::Data Collection::Surveys and Questionnaires HEALTH CARE::Environment and Public Health::Public Health::Epidemiologic Measurements::Demography::Health Status::Quality of Life DISEASES::Respiratory Tract Diseases::Lung Diseases::Lung Diseases, Interstitial::Idiopathic Interstitial Pneumonias::Idiopathic Pulmonary Fibrosis HEALTH CARE::Health Care Economics and Organizations::Economics::Costs and Cost Analysis::Health Care Costs TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::métodos epidemiológicos::recopilación de datos::encuestas y cuestionarios ATENCIÓN DE SALUD::ambiente y salud pública::salud pública::medidas epidemiológicas::demografía::estado de salud::calidad de vida ENFERMEDADES::enfermedades respiratorias::enfermedades pulmonares::enfermedades pulmonares intersticiales::neumonías intersticiales idiopáticas::fibrosis pulmonar idiopática ATENCIÓN DE SALUD::economía y organizaciones para la atención de la salud::economía::costes y análisis de costes::costes de la atención a la salud Acute exacerbation; Economic impact; Idiopathic pulmonary fibrosis Exacerbació aguda; Impacte econòmic; Fibrosi pulmonar idiopàtica Exacerbación aguda; Impacto económico; Fibrosis pulmonar idiopática Background Idiopathic pulmonary fibrosis (IPF) is a fatal progressive lung disease entailing significant impairment in health-related quality of life (HRQoL) and high socioeconomic burden. The course of IPF includes episodes of acute exacerbations (AE-IPF) leading to poor outcomes. This study aimed to compare management, costs and HRQoL of patients with AE-IPF to patients without AE-IPF during one year in Spain. Materials and methods In a 12-month, prospective, observational, multicenter study of IPF patients, healthcare resource use was recorded and costs related to AE-IPF were estimated and compared between patients with and without AE-IPF. HRQoL was measured with the St. George’s Respiratory Questionnaire (SGRQ), EuroQoL 5 dimensions 5 levels questionnaire (EQ-5D-5L), EQ-5D visual analogue scale (EQ-VAS) and the Barthel Index. Results 204 IPF patients were included: 22 (10.8%) experienced ≥ 1 acute exacerbation, and 182 (89.2%) did not. Patients with exacerbations required more primary care visits, nursing home visits, emergency visits, hospital admissions, pharmacological treatments and transport use (p < 0.05 for all comparisons). Likewise, patients with exacerbations showed higher annual direct health AE-IPF-related costs. In particular, specialized visits, emergency visits, days of hospitalization, tests, palliative care, transport in ambulance and economic aid (p < 0.05 for all comparisons). Exploratory results showed that patients with AE-IPF reported a non-significant but substantial decline of HRQoL compared with patients without AE-IPF, although causality can be inferred. Conclusion We observed significantly higher resource use and cost consumption and lower HRQoL among patients suffering exacerbations during the study. Thus, preventing or avoiding AE-IPF is key in IPF management. This work was supported and funded by Boehringer Ingelheim España. 2024-10-04T10:04:13Z 2024-10-04T10:04:13Z 2024-07-31 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Gómez Villar A, Rodríguez-Nieto MJ, Cano-Jiménez E, Romero Ortiz A, Morros M, Ramon A, et al. Clinical and economic burden of acute exacerbations of idiopathic pulmonary fibrosis: a prospective observational study in Spain (OASIS study). BMC Pulm Med. 2024 Jul 31;24:370. 1471-2466 https://hdl.handle.net/11351/12014 10.1186/s12890-024-03186-4 39080648 001281056400001 http://hdl.handle.net/11351/12014 eng BMC Pulmonary Medicine;24 https://doi.org/10.1186/s12890-024-03186-4 Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess application/pdf BMC Scientia